(68)Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review

Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months. The bone metastases were verified by supplementary imaging with (18)F-sodium fluoride PET/CT and magnetic resonance imaging as well as biochemical responses to androgen deprivation therapy. Therefore, (68)Ga-PSMA PET/CT is promising for the restaging of patients with prostate cancer with biochemical recurrence, including patients with low PSA levels and low PSA kinetics.

Molecular and clinical oncology. 2017 May 31 [Epub]

Lars J Petersen, Julie B Nielsen, Katja Dettmann, Rune V Fisker, Uwe Haberkorn, Louise Stenholt, Helle D Zacho

Department of Nuclear Medicine, Clinical Cancer Research Center, Aalborg University Hospital, DK-9000 Aalborg, Denmark., Department of Urology, Regional Hospital West Jutland, DK-7500 Holstebro, Denmark., Department of Nuclear Medicine, University Hospital of Heidelberg, D-69120 Heidelberg, Germany., The Medical Library, Aalborg University Hospital, DK-9000 Aalborg, Denmark.